About CLINUVEL

Mrs Brenda Shanahan

BEc, BCom

Non-Executive Director

Mrs Shanahan has a longstanding background in finance in Australian and overseas’ economies and share markets and is a Fellow of the Institute of Directors. She is currently Chair of St Vincent's Medical Research Institute in Melbourne, a non-executive Director of DMP Asset Management, a non-executive Director of Challenger Limited (ASX:CGF) and a Director of the Kimberley Foundation of Australia. Mrs Shanahan is the former Chair of Challenger Listed Investments Ltd, the reporting entity for Challenger Kenedix Japan Trust (ASX:CKT), Challenger Infrastructure Fund (ASX:CIF), Challenger Diversified Property Group (ASX: CDI) and Challenger Wine Trust (ASX:CWT).

She is a former member of the Australian Stock Exchange and former executive director of a stockbroking firm, a fund management company and an actuarial company. Mrs Shanahan is well known in the business and financial community; her insights add significant value to the current Board and the company. Mrs Shanahan was Non-Executive Chair of the CLINUVEL Board from late 2007 until July 2010.

Latest Company Announcements

19 September 2017

CLINUVEL PROVIDES UPDATE ON SCENESSE® FDA FILING

CLINUVEL PHARMACEUTICALS LTD today announced an update on its submission of the New Drug Application (NDA) for CLINUVEL’s drug SCENESSE® (afamelanotide 16 mg) to the US Food and Drug Administration (FDA).

Read More
06 September 2017

Appendix 3B

Appendix 3B - New issue announcement

Read More
30 August 2017

Appendix 4E - Preliminary Final Report 2016/17

Appendix 4E - Preliminary Final Report 2016/17

Read More
08 August 2017

Form 604, 09 August 2017

Notice of change of interests of substantial holder

Read More
31 July 2017

Appendix 4C - Quarterly report

Appendix 4C

Read More
25 July 2017

CLINUVEL Newsletter - July 2017

For those who have followed the Company over the years, the journey of our teams has most often been counter-current to arrive at the present point.

Read More

Quick Links